Henry F. Van Brocklin, PhD

Henry F. Van Brocklin, PhD

Professor, Department of Radiology, and Director of Radiopharmaceutical Research, UCSF


Phone: (510) 486-4083 (voice)
Lawrence Berkeley Nat'l Laboratory, 1 Cyclotron Road, MS 55-121, Berkeley, CA 94720

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

I have over 25 years’ experience with the preparation and application of radiopharmaceuticals. I have developed several imaging agents targeting cell surface proteins (receptors, enzymes and transporters) including receptor-based imaging agents for hormone receptors, growth factor receptors, neuroreceptors, and prostate-specific membrane antigen. I have developed imaging agents for cardiac blood flow and metabolism. These imaging agents have included a broad range of molecular motifs from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies), and aptamers, to proteins and peptides. These molecules have been labeled with a variety of isotopes for PET and SPECT imaging. As part of the development of these imaging agents, I have been engaged in the evaluation and validation of the tracer mechanism of localization and retention at the target site. I have prepared several in vitro and in vivo model systems and interpreted the data collected from these systems to determine the utility of the probes. I have successfully translated many of these tracers into humans. I have helped to write and secure several INDs for first-in-human tracer studies.
Over the last 10 years, I have been working on the development of PSMA targeting prostate cancer imaging agents in collaboration with Dr. Clifford Berkman at Washington State University. I am currently PI on a DoD PCRP-funded proposal to prepare these agents for human imaging studies. I am also UCSF PI on an NIH SBIR funded to perform the first-in-man PET/MRI imaging studies. I am currently also evaluating a new agent to measure T cell activation, 18F-FAraG. The pharmacokinetics of agent has been assessed in normal human subjects and will be further evaluated following immunotherapy response.


Rensselaer Polytechnic Institute, Troy, NY, B.S., 1984, Chemistry
Rensselaer Polytechnic Institute, Troy, NY, M.S., 1986, Nuclear Chemistry
Washington University, St. Louis, MO, M.A., 1988, Nuclear Chemistry
Washington University, St. Louis, MO, Ph.D., 1990, Radiopharm. Chemistry
University of Illinois, Urbana, IL, Postdoctoral, 1992, Radiopharm. Chemistry

Professional Experience

  • 1990-1992
    DOE Alexander Hollaender Distinguished Postdoctoral Fellow, University of Illinois
  • 1992-present
    Chief Chemist, Head, Radiochemistry, Center for Functional Imaging, Lawrence Berkeley National Laboratory
  • 1992-2005
    Assistant Adjunct Professor of Radiology, University of California San Francisco
  • 2005-present
    Professor of Radiology, University of California San Francisco
  • 2005-present
    Joint Faculty Scientist, Department of Functional Imaging, LBNL

Honors & Awards

  • 1990-1992
    DOE Alexander Hollaender Distinguished Postdoctoral Fellowship
    Lawrence Berkeley National Laboratory Outstanding Performance Award (1993, 1997, 1998, 2000)
  • 2006
    SNM President's Distinguished Service Award

Selected Publications

  • Lagunas-Solar MC, Zeng N, Castaneda CM, Carvacho OF, VanBrocklin HF, Budinger TF. Accelerator Production of 122Xe (20.1 h) as a Source of 122I (3.6 m) Labeled Radiopharmaceuticals for Applications in Positron Emission Tomography. in "Proceedings of the 15th International Conference on the Applications of Accelerators in Research and Industry" Duggan, JL; Morgan, IL. ed. AIP Press 1999; 994-997.
  • O'Neil JP, VanBrocklin HF. Preparation of fluorine-18 gas from a 11 MeV cyclotron: A target system for the CTI RDS 111 cyclotron. Nuc Inst Meth Phys Res Section A 1999; 438(1):166-172.
  • Lim JK, Negash K, VanBrocklin HF. Synthesis of 4-(3'[125I]Iodophenylamino)-6,7-dialkoxyquinazoline: Epidermal Growth Factor Receptor Tyrosine Kinase (EGFrTK) Inhibitors. J Lab Comp Radiopharm 2000; 43:1183-1191.
  • Joosten R, Powell J, Guo FQ, Haustein PE, Larimer R-M, McMahan MA, Norman EB, O'Neil JP, . Rowe MW, VanBrocklin HF, Wutte D, Xu XJ, Joseph Cerny. Measurement of excitation functions in the reactions 197Au(11C,xn)208-xAt using a radioactive 11C beam. Phys Rev Lett 2000; 84:5066-5069.
  • Marshall RC, Powers-Risius P, Reutter BW, Taylor SE, VanBrocklin HF, Huesman RH, Budinger TF. Kinetic Analysis of 7'-[125I]Iodorotenone as a Depositied Myocardial Flow Tracer: Comparison to [99mTc]Sestamibi. J Nucl Med 2001; 42:272-281.
  • Eberling JL, Roberts,JA, Taylor SE, VanBrocklin HF, O'Neil JP, Nordahl TE. Effects of age and estrogen on aromatic L- amino acid decarboxylase activity in rhesus monkey brain. Neurobiology of Aging, 2002; 23(3): 479-83.
  • Lange CW, VanBrocklin HF, Taylor SE. Photoconjugation of 3-azido-5-nitrobenzyl-[18F]fluoride to an ologonucleotide. J Lab Comp Radiopharm 2002; 45: 257-268.
  • Gibbs AR, Morimoto H, Biegon A, VanBrocklin HF, Williams PG. Synthesis of N-(2-chloro-5-methylthiophenyl)-N'-(3-methyl-thiophenyl)-N'-[3H3]methylguanidine, {[3H3]CNS-5161}. J Lab Comp.Radiopharm 2002; 45: 395-400.
  • Collier TL, Lecomte R, McCarthy TJ, Meikle S, Ruth TJ, Scopinaro F, Signore A, VanBrocklin HF, Van de Wiele C, Waterhouse RN. Assessment of Cancer Associated Biomarkers by Positron Emission Tomography: Advances and Challenges. Dis Markers. 2002; 18(5-6):211-47.
  • VanBrocklin HF, Blagoev M, Hoepping A, O'Neil JP, Klose M, Schubiger PA, Ametamey S. A new precursor for the preparation of 6-[18F]-Fluoro-L-m-tyrosine (FMT): Efficient synthesis and comparison of radiolabeling. Appl Rad Isot. 61(6):1289-1294, 2004.
  • Marshall RC, Powers-Risius P, Reutter BW, O'Neil JP, LaBelle M, Huesman RH, VanBrocklin HF; Kinectic Analysis of 18F-Fluorodihydrorotenone as a Deposited Myocardial Flow Tracer: Comparison tozThallium-201. J. Nucl. Med 45(11): 1950-1959, 2004.
  • Vasdev N, Dorff PN, Gibbs AR, Erathodiyil N, Reid L, O'Neill JP, VanBrocklin HF; Synthesis of 6-acrylimido-4-(2-[18F]fluoroanilino)quinazoline; A fluorine-18 labeled irreversible binding probe for EGFR imaging. J Labelled Comp Radiopharm, 48:109-115, 2005.
  • VanBrocklin, HF; Lim,JK; Coffig, SL; Hom, DL; Negash, K; Ono, MY; Hanrahan, SM; Taylor, SE; Vanderpoel, JL; Slavik, SM; Morris, AB; Riese II, DJ. Dialkoxyquinazolines: Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes. J. Med. Chem. 48(23) 7445-7456, 2005.
  • Hwang, AB; Taylor, CC; VanBrocklin, HF; Dae, MW; Hasegawa, BH. Attenuation Correction of Small Animal SPECT Images Acquired with 125I-Iodorotenone. IEEE Transactions on Nuclear Science. 53:1213-1220, 2006.
  • VanBrocklin, HF; Enas, JD; Hanrahan, SM; O'Neil, JP. Mitochondrial Electron Transport Chain (ETC) Radioprobes. Preparation and Evaluation of 7'(E)-[125I]Iodorotenone and 7'(E)-[125I]Iodorotenol. Nucl. Med. Biol. In Press.